Lasmiditan

Drug Profile

Lasmiditan

Alternative Names: COL-144; LY-573144

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Lundbeck A/S
  • Developer CoLucid Pharmaceuticals
  • Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 16 Oct 2017 Eli Lilly plans a phase I trial in Healthy volunteers in USA (PO) (NCT03310411)
  • 12 Oct 2017 Eli Lilly plans a phase I trial in Healthy volunteers in USA (PO) (NCT03308669)
  • 15 Sep 2017 Eli Lilly initiates enrolment in a phase I trial (In volunteers) to determine the potential for abuse of lasmiditan in USA (PO) (NCT03286218)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top